Ribavirin in acute viral hepatitis.

Simple item page
dc.contributor.authorAjgaonkar, V Sen_US
dc.contributor.authorMogre, V Men_US
dc.date.accessioned1991-07-01en_US
dc.date.accessioned2009-05-29T03:16:36Z
dc.date.available1991-07-01en_US
dc.date.available2009-05-29T03:16:36Z
dc.date.issued1991-07-01en_US
dc.description.abstractA double-blind, placebo-controlled trial using ribavirin (200 mg orally four times a day for two weeks) was conducted in 30 patients with acute uncomplicated viral hepatitis (excluding hepatitis B). Clinical and laboratory parameters were evaluated on days 5, 10 and 14 after starting treatment. Mean levels of ALT and AST were significantly lower in the ribavirin treated group as compared to the placebo group on days 5, 10 and 14; serum bilirubin levels were significantly lower in the ribavirin group on days 10 and 14. Ribavirin therapy was not associated with any significant side effects. We conclude that ribavirin therapy in acute uncomplicated non-B viral hepatitis leads to more rapid normalisation of biochemical parameters.en_US
dc.description.affiliationKasturba Hospital, Bombay.en_US
dc.identifier.citationAjgaonkar VS, Mogre VM. Ribavirin in acute viral hepatitis. Indian Journal of Gastroenterology. 1991 Jul; 10(3): 90-1en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/65146
dc.language.isoengen_US
dc.source.urihttps://www.indianjgastro.comen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshHepatitis, Viral, Human --drug therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRibavirin --therapeutic useen_US
dc.titleRibavirin in acute viral hepatitis.en_US
dc.typeClinical Trialen_US
dc.typeJournal Articleen_US
dc.typeRandomized Controlled Trialen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Gastroenterology